A decade from discovery to therapy: Lingo-1, the dark horse in neurological and psychiatric disorders

Neuroscience and Biobehavioral Reviews

Volumn 56, Issue , 2015, Pages 97-114

  Andrews, Jessica L ^a,b   Fernandez Enright, Francesca ^a,b  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

Author keywords

Gene expression; Lingo 1 signaling; Neurological pathologies; Psychiatric disorders; Therapeutic strategies

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MEMBRANE PROTEIN; NOGO RECEPTOR; PEPTIDES AND PROTEINS; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE WNK1; PROTEIN LINGO 1; PROTEIN MYT1; PROTEIN MYT1L; PROTEIN P75; RECEPTOR; TRANSCRIPTION FACTOR; TROY RECEPTOR COMPLEX; UNCLASSIFIED DRUG; LINGO1 PROTEIN, HUMAN; NERVE PROTEIN;

ALZHEIMER DISEASE; CORTICAL DYSPLASIA; ESSENTIAL TREMOR; GENE EXPRESSION; GENE FUNCTION; GENE STRUCTURE; GLAUCOMA; HUMAN; LINGO 1 GENE; MENTAL DISEASE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SPINAL CORD INJURY; TEMPORAL LOBE EPILEPSY; TRAUMATIC BRAIN INJURY; TUBEROUS SCLEROSIS; ANIMAL; MENTAL DISORDERS; METABOLISM; NERVOUS SYSTEM DISEASES; PRECLINICAL STUDY;

ANIMALS; DRUG EVALUATION, PRECLINICAL; HUMANS; MEMBRANE PROTEINS; MENTAL DISORDERS; NERVE TISSUE PROTEINS; NERVOUS SYSTEM DISEASES;

EID: 84936865701     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2015.06.009     Document Type: Review

References (247)

1. Abe O., Yamasue H., Kasai K., Yamada H., Aoki S., Iwanami A., Ohtani T., Masutani Y., Kato N., Ohtomo K. Voxel-based diffusion tensor analysis reveals aberrant anterior cingulum integrity in posttraumatic stress disorder due to terrorism. Psychiatry Res. 2006, 146:231-242. DOI 10.1016/j.pscychresns.2006.01.004.
2. Adler C.M., Adams J., DelBello M.P., Holland S.K., Schmithorst V., Levine A., Jarvis K., Strakowski S.M. Evidence of white matter pathology in bipolar disorder adolescents experiencing their first episode of mania: a diffusion tensor imaging study. Am. J. Psychiatry 2006, 163:322-324. DOI 10.1176/appi.ajp.163.2.322.
3. Adler C.M., Holland S.K., Schmithorst V., Wilke M., Weiss K.L., Pan H., Strakowski S.M. Abnormal frontal white matter tracts in bipolar disorder: a diffusion tensor imaging study. Bipolar Disord. 2004, 6:197-203. DOI 10.1111/j.1399-5618.2004.00108.x.
4. Akbik F., Cafferty W.B., Strittmatter S.M. Myelin associated inhibitors: a link between injury-induced and experience-dependent plasticity. Exp. Neurol. 2012, 235:43-52. DOI S0014-4886(11)00228-7 10.1016/j.expneurol.2011.06.006.
5. Aleman A., Hijman R., de Haan E.H., Kahn R.S. Memory impairment in schizophrenia: a meta-analysis. Am. J. Psychiatry 1999, 156:1358-1366.
6. Alexopoulos G.S., Kiosses D.N., Choi S.J., Murphy C.F., Lim K.O. Frontal white matter microstructure and treatment response of late-life depression: a preliminary study. Am. J. Psychiatry 2002, 159:1929-1932.
7. Armstrong R.C., Kim J.G., Hudson L.D. Expression of myelin transcription factor I (MyTI), a "zinc-finger" DNA-binding protein, in developing oligodendrocytes. Glia 1995, 14:303-321. DOI 10.1002/glia.440140407.
8. Armstrong R.C., Migneault A., Shegog M.L., Kim J.G., Hudson L.D., Hessler R.B. High-grade human brain tumors exhibit increased expression of myelin transcription factor 1 (MYT1), a zinc finger DNA-binding protein. J. Neuropathol. Exp. Neurol. 1997, 56:772-781.
9. Åsberg M., Nygren Å., Leopardi R., Rylander G., Peterson U., Wilczek L., Källmén H., Ekstedt M., Åkerstedt T., Lekander M., Ekman R. Novel biochemical markers of psychosocial stress in women. PLoS ONE 2009, 4:e3590. DOI 10.1371/journal.pone.0003590.
10. Aston C., Jiang L., Sokolov B.P. Transcriptional profiling reveals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder. Mol. Psychiatry 2005, 10:309-322. DOI 10.1038/sj.mp.4001565.
11. Bae J.N., MacFall J.R., Krishnan K.R.R., Payne M.E., Steffens D.C., Taylor W.D. Dorsolateral prefrontal cortex and anterior cingulate cortex white matter alterations in late-life depression. Biol. Psychiatry 2006, 60:1356-1363. DOI 10.1016/j.biopsych.2006.03.052.
12. Bai Y., Markham K., Chen F., Weerasekera R., Watts J., Horne P., Wakutani Y., Bagshaw R., Mathews P.M., Fraser P.E., Westaway D., St George-Hyslop P., Schmitt-Ulms G. The in vivo brain interactome of the amyloid precursor protein. Mol. Cell. Proteomics MCP 2008, 7:15-34. DOI 10.1074/mcp.M700077-MCP200.
13. Barch D.M., Carter C.S., Braver T.S., Sabb F.W., MacDonald A., Noll D.C., Cohen J.D. Selective deficits in prefrontal cortex function in medication-naive patients with schizophrenia. Arch. Gen. Psychiatry 2001, 58:280-288. DOI yoa20124 .
14. Barker P.A. p75NTR is positively promiscuous: novel partners and new insights. Neuron 2004, 42:529-533. DOI 10.1016/j.neuron.2004.04.001.
15. Barley K., Dracheva S., Byne W. Subcortical oligodendrocyte- and astrocyte-associated gene expression in subjects with schizophrenia, major depression and bipolar disorder. Schizophr. Res. 2009, 112:54-64. DOI 10.1016/j.schres.2009.04.019.
16. Bartzokis G., Nuechterlein K.H., Lu P.H., Gitlin M., Rogers S., Mintz J. Dysregulated brain development in adult men with schizophrenia: a magnetic resonance imaging study. Biol. Psychiatry 2003, 53:412-421.
17. Bassett A.S., Chow E.W. 22q11 deletion syndrome: a genetic subtype of schizophrenia. Biol. Psychiatry 1999, 46:882-891. DOI S0006-3223(99)00114-6 .
18. Bassett A.S., Chow E.W., AbdelMalik P., Gheorghiu M., Husted J., Weksberg R. The schizophrenia phenotype in 22q11 deletion syndrome. Am. J. Psychiatry 2003, 160:1580-1586.
19. Bech-Hansen N.T., Naylor M.J., Maybaum T.A., Sparkes R.L., Koop B., Birch D.G., Bergen A.A., Prinsen C.F., Polomeno R.C., Gal A., Drack A.V., Musarella M.A., Jacobson S.G., Young R.S., Weleber R.G. Mutations in NYX, encoding the leucine-rich proteoglycan nyctalopin, cause X-linked complete congenital stationary night blindness. Nat. Genet. 2000, 26:319-323. DOI 10.1038/81619.
20. Bellefroid E.J., Bourguignon C., Hollemann T., Ma Q., Anderson D.J., Kintner C., Pieler T. X-MyT1, a Xenopus C2HC-type zinc finger protein with a regulatory function in neuronal differentiation. Cell 1996, 87:1191-1202.
21. Beuten J., Ma J.Z., Payne T.J., Dupont R.T., Lou X.-Y., Crews K.M., Elston R.C., Li M.D. Association of specific haplotypes of neurotrophic tyrosine kinase receptor 2 gene (NTRK2) with vulnerability to nicotine dependence in African-Americans and European-Americans. Biol. Psychiatry 2007, 61:48-55. DOI 10.1016/j.biopsych.2006.02.023.
22. Białecka M., Kurzawski M., Tan E.-K., Drozdzik M. Analysis of LINGO1 (rs9652490) polymorphism in sporadic Parkinson's disease in a Polish population, and a meta-analysis. Neurosci. Lett. 2010, 472:53-55. DOI 10.1016/j.neulet.2010.01.055.
23. Bormann P., Roth L.W., Andel D., Ackermann M., Reinhard E. zfNLRR, a novel leucine-rich repeat protein is preferentially expressed during regeneration in zebrafish. Mol. Cell. Neurosci. 1999, 13:167-179. DOI 10.1006/mcne.1999.0742.
24. Brabeck C., Beschorner R., Conrad S., Mittelbronn M., Bekure K., Meyermann R., Schluesener H.J., Schwab J.M. Lesional expression of RhoA and RhoB following traumatic brain injury in humans. J. Neurotrauma 2004, 21:697-706. DOI 10.1089/0897715041269597.
25. Breier A., Buchanan R.W., Elkashef A., Munson R.C., Kirkpatrick B., Gellad F. Brain morphology and schizophrenia. A magnetic resonance imaging study of limbic, prefrontal cortex, and caudate structures. Arch. Gen. Psychiatry 1992, 49:921-926.
26. Brose K., Bland K.S., Wang K.H., Arnott D., Henzel W., Goodman C.S., Tessier-Lavigne M., Kidd T. Slit proteins bind Robo receptors and have an evolutionarily conserved role in repulsive axon guidance. Cell 1999, 96:795-806.
27. Brose K., Tessier-Lavigne M. Slit proteins: key regulators of axon guidance, axonal branching, and cell migration. Curr. Opin. Neurobiol. 2000, 10:95-102.
28. Brugarolas P., Popko B. Remyelination therapy goes to trial for multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 2014, 1:e26. DOI 10.1212/NXI.0000000000000026.
29. Brunet A., Datta S.R., Greenberg M.E. Transcription-dependent and independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr. Opin. Neurobiol. 2001, 11:297-305. DOI S0959-4388(00)00211-7 .
30. Buchanan R.W., Vladar K., Barta P.E., Pearlson G.D. Structural evaluation of the prefrontal cortex in schizophrenia. Am. J. Psychiatry 1998, 155:1049-1055.
31. Buchsbaum M.S., Tang C.Y., Peled S., Gudbjartsson H., Lu D., Hazlett E.A., Downhill J., Haznedar M., Fallon J.H., Atlas S.W. MRI white matter diffusion anisotropy and PET metabolic rate in schizophrenia. NeuroReport 1998, 9:425-430.
32. Budel S. Nogo-66 Receptor Dysfunction Increases the Risk of Schizophrenia 2007, Yale University, Ann Arbor, MI.
33. Budel S., Padukkavidana T., Liu B.P., Feng Z., Hu F., Johnson S., Lauren J., Park J.H., McGee A.W., Liao J., Stillman A., Kim J.E., Yang B.Z., Sodi S., Gelernter J., Zhao H., Hisama F., Arnsten A.F., Strittmatter S.M. Genetic variants of Nogo-66 receptor with possible association to schizophrenia block myelin inhibition of axon growth. J. Neurosci. 2008, 28:13161-13172. DOI 28/49/13161 10.1523/JNEUROSCI.3828-08.2008.
34. Callicott J.H., Bertolino A., Mattay V.S., Langheim F.J., Duyn J., Coppola R., Goldberg T.E., Weinberger D.R. Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb. Cortex 2000, 10:1078-1092.
35. Cannistraro P.A., Makris N., Howard J.D., Wedig M.M., Hodge S.M., Wilhelm S., Kennedy D.N., Rauch S.L. A diffusion tensor imaging study of white matter in obsessive-compulsive disorder. Depress. Anxiety 2007, 24:440-446. DOI 10.1002/da.20246.
36. Carim-Todd L., Escarceller M., Estivill X., Sumoy L. LRRN6A/LERN1 (leucine-rich repeat neuronal protein 1), a novel gene with enriched expression in limbic system and neocortex. Eur. J. Neurosci. 2003, 18:3167-3182.
37. Carlson C., Papolos D., Pandita R.K., Faedda G.L., Veit S., Goldberg R., Shprintzen R., Kucherlapati R., Morrow B. Molecular analysis of velo-cardio-facial syndrome patients with psychiatric disorders. Am. J. Hum. Genet. 1997, 60:851-859.
38. Caroni P., Schwab M.E. Antibody against myelin-associated inhibitor of neurite growth neutralizes nonpermissive substrate properties of CNS white matter. Neuron 1988, 1:85-96.
39. Carter C.J. Schizophrenia susceptibility genes converge on interlinked pathways related to glutamatergic transmission and long-term potentiation, oxidative stress and oligodendrocyte viability. Schizophr. Res. 2006, 86:1-14. DOI 10.1016/j.schres.2006.05.023.
40. Carter C.S. Re-conceptualizing schizophrenia as a disorder of cognitive and emotional processing: a shot in the arm for translational research. Biol. Psychiatry 2006, 60:1169-1170. DOI 10.1016/j.biopsych.2006.10.024.
41. Castellanos F.X., Sharp W.S., Gottesman R.F., Greenstein D.K., Giedd J.N., Rapoport J.L. Anatomic brain abnormalities in monozygotic twins discordant for attention deficit hyperactivity disorder. Am. J. Psychiatry 2003, 160:1693-1696.
42. Catts V.S., Al-Menhali N., Burne T.H.J., Colditz M.J., Coulson E.J. The p75 neurotrophin receptor regulates hippocampal neurogenesis and related behaviours. Eur. J. Neurosci. 2008, 28:883-892. DOI 10.1111/j.1460-9568.2008.06390.x.
43. Chen J.H., Wen L., Dupuis S., Wu J.Y., Rao Y. The N-terminal leucine-rich regions in Slit are sufficient to repel olfactory bulb axons and subventricular zone neurons. J. Neurosci. 2001, 21:1548-1556. (Off. J. Soc. Neurosci.).
44. Chen M.S., Huber A.B., van der Haar M.E., Frank M., Schnell L., Spillmann A.A., Christ F., Schwab M.E. Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature 2000, 403:434-439. DOI 10.1038/35000219.
45. Chen Y., Aulia S., Li L., Tang B.L. AMIGO and friends: an emerging family of brain-enriched, neuronal growth modulating, type I transmembrane proteins with leucine-rich repeats (LRR) and cell adhesion molecule motifs. Brain Res. Rev. 2006, 51:265-274. DOI 10.1016/j.brainresrev.2005.11.005.
46. Choate K.A., Kahle K.T., Wilson F.H., Nelson-Williams C., Lifton R.P. WNK1, a kinase mutated in inherited hypertension with hyperkalemia, localizes to diverse Cl--transporting epithelia. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:663-668. DOI 10.1073/pnas.242728499.
47. Cho C.-H. Frontier of epilepsy research-mTOR signaling pathway. Exp. Mol. Med. 2011, 43:231-274. DOI 10.3858/emm.2011.43.5.032.
48. Conti A.C., Raghupathi R., Trojanowski J.Q., McIntosh T.K. Experimental brain injury induces regionally distinct apoptosis during the acute and delayed post-traumatic period. J. Neurosci. 1998, 18:5663-5672. (Off. J. Soc. Neurosci.).
49. Cuscó I., Medrano A., Gener B., Vilardell M., Gallastegui F., Villa O., González E., Rodríguez-Santiago B., Vilella E., Campo M.D., Pérez-Jurado L.A. Autism-specific copy number variants further implicate the phosphatidylinositol signaling pathway and the glutamatergic synapse in the etiology of the disorder. Hum. Mol. Genet. 2009, 18:1795-1804. DOI 10.1093/hmg/ddp092.
50. Davis K.L., Haroutunian V. Global expression-profiling studies and oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003, 362:758. DOI 10.1016/S0140-6736(03)14297-3.
51. Davis K.L., Stewart D.G., Friedman J.I., Buchsbaum M., Harvey P.D., Hof P.R., Buxbaum J., Haroutunian V. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch. Gen. Psychiatry 2003, 60:443-456. DOI 10.1001/archpsyc.60.5.443 60/5/443 .
52. Dechant G., Barde Y.-A. The neurotrophin receptor p75(NTR): novel functions and implications for diseases of the nervous system. Nat. Neurosci. 2002, 5:1131-1136. DOI 10.1038/nn1102-1131.
53. De Laat R., Meabon J.S., Wiley J.C., Hudson M.P., Montine T.J., Bothwell M. LINGO-1 promotes lysosomal degradation of amyloid-β protein precursor. Pathobiol. Aging Age Relat. Dis. 2015, 5. 10.3402/pba.v5.25796.
54. Deng H., Le W., Jankovic J. Genetics of essential tremor. Brain J. Neurol. 2007, 130:1456-1464. DOI 10.1093/brain/awm018.
55. De Rijk M.C., Launer L.J., Berger K., Breteler M.M., Dartigues J.F., Baldereschi M., Fratiglioni L., Lobo A., Martinez-Lage J., Trenkwalder C., Hofman A. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000, 54:S21-S23.
56. Domeniconi M., Cao Z., Spencer T., Sivasankaran R., Wang K., Nikulina E., Kimura N., Cai H., Deng K., Gao Y., He Z., Filbin M. Myelin-associated glycoprotein interacts with the Nogo66 receptor to inhibit neurite outgrowth. Neuron 2002, 35:283-290.
57. Dubreuil C.I., Marklund N., Deschamps K., McIntosh T.K., McKerracher L. Activation of Rho after traumatic brain injury and seizure in rats. Exp. Neurol. 2006, 198:361-369. DOI 10.1016/j.expneurol.2005.12.002.
58. Dunham J.S., Deakin J.F.W., Miyajima F., Payton A., Toro C.T. Expression of hippocampal brain-derived neurotrophic factor and its receptors in Stanley consortium brains. J. Psychiatr. Res. 2009, 43:1175-1184. DOI 10.1016/j.jpsychires.2009.03.008.
59. Dwivedi Y., Rizavi H.S., Conley R.R., Roberts R.C., Tamminga C.A., Pandey G.N. Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch. Gen. Psychiatry 2003, 60:804-815. DOI 10.1001/archpsyc.60.8.804.
60. El-Hattab A.W., Smolarek T.A., Walker M.E., Schorry E.K., Immken L.L., Patel G., Abbott M.-A., Lanpher B.C., Ou Z., Kang S.-H.L., Patel A., Scaglia F., Lupski J.R., Cheung S.W., Stankiewicz P. Redefined genomic architecture in 15q24 directed by patient deletion/duplication breakpoint mapping. Hum. Genet. 2009, 126:589-602. DOI 10.1007/s00439-009-0706-x.
61. El-Hattab A.W., Zhang F., Maxim R., Christensen K.M., Ward J.C., Hines-Dowell S., Scaglia F., Lupski J.R., Cheung S.W. Deletion and duplication of 15q24: molecular mechanisms and potential modification by additional copy number variants. Genet. Med. 2010, 12:573-586. DOI 10.1097/GIM.0b013e3181eb9b4a.
62. Ernst C., Wanner B., Brezo J., Vitaro F., Tremblay R., Turecki G. A deletion in tropomyosin-related kinase B and the development of human anxiety. Biol. Psychiatry 2011, 69:604-607. DOI 10.1016/j.biopsych.2010.10.008.
63. Fahnestock M., Nicolini C. Abnormalities in BDNF/TrkB/PI3K signaling pathways in autism (728.3). FASEB J. 2014, 28:728. (3).
64. Farkas L.M., Krieglstein K. Heparin-binding epidermal growth factor-like growth factor (HB-EGF) regulates survival of midbrain dopaminergic neurons. J. Neural Transm. 2002, 109:267-277. DOI 10.1007/s007020200022. (Vienna Austria, 1996).
65. Fekete R., Jankovic J. Revisiting the relationship between essential tremor and Parkinson's disease. Mov. Disord. 2011, 26:391-398. DOI 10.1002/mds.23512. (Off. J. Mov. Disord. Soc.).
66. Fernandez-Enright F., Andrews J.L., Newell K.A., Pantelis C., Huang X.F. Novel implications of Lingo-1 and its signaling partners in schizophrenia. Transl. Psychiatry 2014, 4:e348. DOI 10.1038/tp.2013.121.
67. Filipek P.A., Semrud-Clikeman M., Steingard R.J., Renshaw P.F., Kennedy D.N., Biederman J. Volumetric MRI analysis comparing subjects having attention-deficit hyperactivity disorder with normal controls. Neurology 1997, 48:589-601.
68. Foster T.C. Involvement of hippocampal synaptic plasticity in age-related memory decline. Brain Res. Rev. 1999, 30:236-249. DOI 10.1016/S0165-0173(99)00017-X.
69. Fournier A.E., GrandPre T., Strittmatter S.M. Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration. Nature 2001, 409:341-346. DOI 10.1038/35053072.
70. Franowicz J.S., Kessler L.E., Borja C.M., Kobilka B.K., Limbird L.E., Arnsten A.F. Mutation of the alpha2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine. J. Neurosci. 2002, 22:8771-8777. DOI 22/19/8771 .
71. Fujii T., Kunugi H. p75NTR as a therapeutic target for neuropsychiatric diseases. Curr. Mol. Pharmacol. 2009, 2:70-76.
72. Fung S.J., Webster M.J., Sivagnanasundaram S., Duncan C., Elashoff M., Weickert C.S. Expression of interneuron markers in the dorsolateral prefrontal cortex of the developing human and in schizophrenia. Am. J. Psychiatry 2010, 167:1479-1488. DOI appi.ajp.2010.09060784 10.1176/appi.ajp.2010.09060784.
73. Fu Q.-L., Hu B., Li X., Shao Z., Shi J.-B., Wu W., So K.-F., Mi S. LINGO-1 negatively regulates TrkB phosphorylation after ocular hypertension. Eur. J. Neurosci. 2010, 31:1091-1097. DOI 10.1111/j.1460-9568.2010.07127.x.
74. Fu Q.-L., Hu B., Wu W., Pepinsky R.B., Mi S., So K.-F. Blocking LINGO-1 function promotes retinal ganglion cell survival following ocular hypertension and optic nerve transection. Invest. Ophthalmol. Vis. Sci. 2008, 49:975-985. DOI 10.1167/iovs.07-1199.
75. Fu Q.-L., Liao X.-X., Li X., Chen D., Shi J., Wen W., Lee D.H.S., So K.-F. Soluble Nogo-66 receptor prevents synaptic dysfunction and rescues retinal ganglion cell loss in chronic glaucoma. Invest. Ophthalmol. Vis. Sci. 2011, 52:8374-8380. DOI 10.1167/iovs.11-7667.
76. Fu Q.-L., Li X., Yip H.K., Shao Z., Wu W., Mi S., So K.-F. Combined effect of brain-derived neurotrophic factor and LINGO-1 fusion protein on long-term survival of retinal ganglion cells in chronic glaucoma. Neuroscience 2009, 162:375-382. DOI 10.1016/j.neuroscience.2009.04.075.
77. Garbett K.A., Vereczkei A., Kálmán S., Brown J.A., Taylor W.D., Faludi G., Korade Z., Shelton R.C., Mirnics K. Coordinated messenger RNA/microRNA changes in fibroblasts of patients with major depression. Biol. Psychiatry 2014, DOI 10.1016/j.biopsych.2014.05.015.
78. García-Martín E., Lorenzo-Betancor O., Martínez C., Pastor P., Benito-León J., Millán-Pascual J., Calleja P., Díaz-Sánchez M., Pisa D., Turpín-Fenoll L., Alonso-Navarro H., Ayuso-Peralta L., Torrecillas D., Lorenzo E., Plaza-Nieto J.F., Agúndez J.A., Jiménez-Jiménez F.J. LINGO1 rs9652490 and rs11856808 polymorphisms are not associated with risk for multiple sclerosis. BMC Neurol. 2013, 13:34. DOI 10.1186/1471-2377-13-34.
79. Goffin K., Paesschen W.V., Laere K.V. In vivo activation of endocannabinoid system in temporal lobe epilepsy with hippocampal sclerosis. Brain 2011, 134:1033-1040. DOI 10.1093/brain/awq385.
80. Goldoni S., Iozzo R.A., Kay P., Campbell S., McQuillan A., Agnew C., Zhu J.X., Keene D.R., Reed C.C., Iozzo R.V. A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity. Oncogene 2007, 26:368-381. DOI 1209803 10.1038/sj.onc.1209803.
81. GrandPré T., Nakamura F., Vartanian T., Strittmatter S.M. Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein. Nature 2000, 403:439-444. DOI 10.1038/35000226.
82. Gratacòs M., Nadal M., Martín-Santos R., Pujana M.A., Gago J., Peral B., Armengol L., Ponsa I., Miró R., Bulbena A., Estivill X. A polymorphic genomic duplication on human chromosome 15 is a susceptibility factor for panic and phobic disorders. Cell 2001, 106:367-379.
83. Gupta V.K., You Y., Gupta V.B., Klistorner A., Graham S.L. TrkB receptor signalling: implications in neurodegenerative, psychiatric and proliferative disorders. Int. J. Mol. Sci. 2013, 14:10122-10142. DOI 10.3390/ijms140510122.
84. Gur G., Rubin C., Katz M., Amit I., Citri A., Nilsson J., Amariglio N., Henriksson R., Rechavi G., Hedman H., Wides R., Yarden Y. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J. 2004, 23:3270-3281. DOI 10.1038/sj.emboj.7600342 7600342 .
85. Hakak Y., Walker J.R., Li C., Wong W.H., Davis K.L., Buxbaum J.D., Haroutunian V., Fienberg A.A. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:4746-4751. DOI 10.1073/pnas.081071198 98/8/4746 .
86. Halegoua S., Armstrong R.C., Kremer N.E. Dissecting the mode of action of a neuronal growth factor. Curr. Top. Microbiol. Immunol. 1991, 165:119-170.
87. Hanks S.K., Quinn A.M., Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 1988, 241:42-52.
88. Hannestad J., Taylor W.D., McQuoid D.R., Payne M.E., Krishnan K.R.R., Steffens D.C., Macfall J.R. White matter lesion volumes and caudate volumes in late-life depression. Int. J. Geriatr. Psychiatry 2006, 21:1193-1198. DOI 10.1002/gps.1640.
89. Han Y., Fan X., Sun K., Wang X., Wang Y., Chen J., Zhen Y., Zhang W., Hui R. Hypertension associated polymorphisms in WNK1/WNK4 are not associated with hydrochlorothiazide response. Clin. Biochem. 2011, 44:1045-1049. DOI 10.1016/j.clinbiochem.2011.06.008.
90. Heinzelmann M., Reddy S.Y., French L.M., Wang D., Lee H., Barr T., Baxter T., Mysliwiec V., Gill J. Military personnel with chronic symptoms following blast traumatic brain injury have differential expression of neuronal recovery and epidermal growth factor receptor genes. Front. Neurol. 2014, 5. DOI 10.3389/fneur.2014.00198.
91. Henrichsen C.N., Delorme R., Boucherie M., Marelli D., Baud P., Bellivier F., Courtet P., Chabane N., Henry C., Leboyer M., Malafosse A., Antonarakis S.E., Dahoun S. No association between DUP25 and anxiety disorders. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2004, 128B:80-83. DOI 10.1002/ajmg.b.30037. (Off. Publ. Int. Soc. Psychiatr. Genet.).
92. He X.L., Bazan J.F., McDermott G., Park J.B., Wang K., Tessier-Lavigne M., He Z., Garcia K.C. Structure of the Nogo receptor ectodomain: a recognition module implicated in myelin inhibition. Neuron 2003, 38:177-185.
93. Hisaoka T., Morikawa Y., Kitamura T., Senba E. Expression of a member of tumor necrosis factor receptor superfamily, TROY, in the developing mouse brain. Brain Res. Dev. Brain Res. 2003, 143:105-109.
94. Huang E.J., Reichardt L.F. Neurotrophins: roles in neuronal development and function. Annu. Rev. Neurosci. 2001, 24:677-736. DOI 10.1146/annurev.neuro.24.1.677 24/1/677 .
95. Huang X.F., Chen J. Neuregulin 1, brain region specificity and PI3K/Akt in schizophrenia: comment on "Neuregulin 1 ICE-single nucleotide polymorphism in first episode schizophrenia correlates with cerebral activation in fronto-temporal area.". Eur. Arch. Psychiatry Clin. Neurosci. 2009, 259:307-308. DOI 10.1007/s00406-008-0866-z.
96. Hu F., Strittmatter S.M. Regulating axon growth within the postnatal central nervous system. Semin. Perinatol. 2004, 28:371-378.
97. Hu X.-Y., Zhang H.-Y., Qin S., Xu H., Swaab D.F., Zhou J.-N. Increased p75(NTR) expression in hippocampal neurons containing hyperphosphorylated tau in Alzheimer patients. Exp. Neurol. 2002, 178:104-111.
98. Inoue H., Lin L., Lee X., Shao Z., Mendes S., Snodgrass-Belt P., Sweigard H., Engber T., Pepinsky B., Yang L., Beal M.F., Mi S., Isacson O. Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:14430-14435. DOI 0700901104 10.1073/pnas.0700901104.
99. Iritani S., Niizato K., Nawa H., Ikeda K., Emson P.C. Immunohistochemical study of brain-derived neurotrophic factor and its receptor, TrkB, in the hippocampal formation of schizophrenic brains. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:801-807. DOI 10.1016/S0278-5846(03)00112-X.
100. Işeri E., Güney E., Ceylan M.F., Yücel A., Aral A., Bodur Ş., Şener Ş. Increased serum levels of epidermal growth factor in children with autism. J. Autism Dev. Disord. 2011, 41:237-241. DOI 10.1007/s10803-010-1046-3.
101. Ishii N., Wanaka A., Tohyama M. Increased expression of NLRR-3 mRNA after cortical brain injury in mouse. Brain Res. Mol. Brain Res. 1996, 40:148-152.
102. Iwakura Y., Piao Y.-S., Mizuno M., Takei N., Kakita A., Takahashi H., Nawa H. Influences of dopaminergic lesion on epidermal growth factor-ErbB signals in Parkinson's disease and its model: neurotrophic implication in nigrostriatal neurons. J. Neurochem. 2005, 93:974-983. DOI 10.1111/j.1471-4159.2005.03073.x.
103. Jarrard L.E. Retrograde amnesia and consolidation: anatomical and lesion considerations. Hippocampus 2001, 11:43-49. DOI 10.1002/1098-1063(2001)11:1<43::AID-HIPO1018>3.0.CO;2-B.
104. Jayarajan R.N., Venkatasubramanian G., Viswanath B., Janardhan Reddy Y.C., Srinath S., Vasudev M.K., Chandrashekar C.R. White matter abnormalities in children and adolescents with obsessive-compulsive disorder: a diffusion tensor imaging study. Depress. Anxiety 2012, 29:780-788. DOI 10.1002/da.21890.
105. Jiang Z.Y., Zhou Q.L., Holik J., Patel S., Leszyk J., Coleman K., Chouinard M., Czech M.P. Identification of WNK1 as a substrate of Akt/protein kinase B and a negative regulator of insulin-stimulated mitogenesis in 3T3-L1 cells. J. Biol. Chem. 2005, 280:21622-21628. DOI 10.1074/jbc.M414464200.
106. Ji B., Li M., Wu W.T., Yick L.W., Lee X., Shao Z., Wang J., So K.F., McCoy J.M., Pepinsky R.B., Mi S., Relton J.K. LINGO-1 antagonist promotes functional recovery and axonal sprouting after spinal cord injury. Mol. Cell. Neurosci. 2006, 33:311-320. DOI S1044-7431(06)00184-9 10.1016/j.mcn.2006.08.003.
107. Jiménez-Jiménez F.J., García-Martín E., Lorenzo-Betancor O., Pastor P., Alonso-Navarro H., Agúndez J.A.G. LINGO1 and risk for essential tremor: results of a meta-analysis of rs9652490 and rs11856808. J. Neurol. Sci. 2012, 317:52-57. DOI 10.1016/j.jns.2012.02.030.
108. Josephson A., Trifunovski A., Scheele C., Widenfalk J., Wahlestedt C., Brene S., Olson L., Spenger C. Activity-induced and developmental downregulation of the Nogo receptor. Cell Tissue Res. 2003, 311:333-342. DOI 10.1007/s00441-002-0695-8.
109. Kajava A.V., Vassart G., Wodak S.J. Modeling of the three-dimensional structure of proteins with the typical leucine-rich repeats. Structure 1995, 3:867-877. (Lond. Engl. 1993).
110. Kalachikov S., Evgrafov O., Ross B., Winawer M., Barker-Cummings C., Martinelli Boneschi F., Choi C., Morozov P., Das K., Teplitskaya E., Yu A., Cayanis E., Penchaszadeh G., Kottmann A.H., Pedley T.A., Hauser W.A., Ottman R., Gilliam T.C. Mutations in LGI1 cause autosomal-dominant partial epilepsy with auditory features. Nat. Genet. 2002, 30:335-341. DOI 10.1038/ng832.
111. Karayiorgou M., Morris M.A., Morrow B., Shprintzen R.J., Goldberg R., Borrow J., Gos A., Nestadt G., Wolyniec P.S., Lasseter V.K. Schizophrenia susceptibility associated with interstitial deletions of chromosome 22q11. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:7612-7616.
112. Keller T.A., Kana R.K., Just M.A. A developmental study of the structural integrity of white matter in autism. NeuroReport 2007, 18:23-27. DOI 10.1097/01.wnr.0000239965.21685.99.
113. Khachaturian Z.S. Diagnosis of Alzheimer's disease. Arch. Neurol. 1985, 42:1097-1105.
114. Kiholm Lund A.-B., Hove H.D., Kirchhoff M. A 15q24 microduplication, reciprocal to the recently described 15q24 microdeletion, in a boy sharing clinical features with 15q24 microdeletion syndrome patients. Eur. J. Med. Genet. 2008, 51:520-526. DOI 10.1016/j.ejmg.2008.07.008.
115. Kim J.E., Liu B.P., Park J.H., Strittmatter S.M. Nogo-66 receptor prevents raphespinal and rubrospinal axon regeneration and limits functional recovery from spinal cord injury. Neuron 2004, 44:439-451. DOI S0896627304006737 10.1016/j.neuron.2004.10.015.
116. Kim J.G., Armstrong R.C., v Agoston D., Robinsky A., Wiese C., Nagle J., Hudson L.D. Myelin transcription factor 1 (Myt1) of the oligodendrocyte lineage, along with a closely related CCHC zinc finger, is expressed in developing neurons in the mammalian central nervous system. J. Neurosci. Res. 1997, 50:272-290.
117. Kim M.J., Lyoo I.K., Kim S.J., Sim M., Kim N., Choi N., Jeong D.-U., Covell J., Renshaw P.F. Disrupted white matter tract integrity of anterior cingulate in trauma survivors. NeuroReport 2005, 16:1049-1053.
118. Kim S.J., Jeong D.-U., Sim M.E., Bae S.C., Chung A., Kim M.J., Chang K.H., Ryu J., Renshaw P.F., Lyoo I.K. Asymmetrically altered integrity of cingulum bundle in posttraumatic stress disorder. Neuropsychobiology 2006, 54:120-125. DOI 10.1159/000098262.
119. Kobe B., Deisenhofer J. The leucine-rich repeat: a versatile binding motif. Trends Biochem. Sci. 1994, 19:415-421.
120. Kobe B., Kajava A.V. The leucine-rich repeat as a protein recognition motif. Curr. Opin. Struct. Biol. 2001, 11:725-732.
121. Kojima T., Morikawa Y., Copeland N.G., Gilbert D.J., Jenkins N.A., Senba E., Kitamura T. TROY, a newly identified member of the tumor necrosis factor receptor superfamily, exhibits a homology with Edar and is expressed in embryonic skin and hair follicles. J. Biol. Chem. 2000, 275:20742-20747. DOI 10.1074/jbc.M002691200.
122. Koprivica V., Cho K.S., Park J.B., Yiu G., Atwal J., Gore B., Kim J.A., Lin E., Tessier-Lavigne M., Chen D.F., He Z. EGFR activation mediates inhibition of axon regeneration by myelin and chondroitin sulfate proteoglycans. Science 2005, 310:106-110. DOI 310/5745/106 10.1126/science.1115462.
123. Koros E., Dorner-Ciossek C. The role of glycogen synthase kinase-3beta in schizophrenia. Drug News Perspect. 2007, 20:437-445. DOI 1149632 10.1358/dnp.2007.20.7.1149632.
124. Kozma C. On cognitive variability in velocardiofacial syndrome: profound mental retardation and autism. Am. J. Med. Genet. 1998, 81:269-270.
125. Krishnan V., Han M.-H., Mazei-Robison M., Iñiguez S.D., Ables J.L., Vialou V., Berton O., Ghose S., Covington H.E., Wiley M.D., Henderson R.P., Neve R.L., Eisch A.J., Tamminga C.A., Russo S.J., Bolaños C.A., Nestler E.J. AKT signaling within the ventral tegmental area regulates cellular and behavioral responses to stressful stimuli. Biol. Psychiatry 2008, 64:691-700. DOI 10.1016/j.biopsych.2008.06.003. (Stress and Mood Disorders).
126. Kroepfl T., Petek E., Schwarzbraun T., Kroisel P., Plecko B. Mental retardation in a girl with a subtelomeric deletion on chromosome 20q and complete deletion of the myelin transcription factor 1 gene (MYT1). Clin. Genet. 2008, 73:492-495. DOI 10.1111/j.1399-0004.2008.00982.x.
127. Kuo S.-H., Tang G., Louis E.D., Ma K., Babji R., Balatbat M., Cortes E., Vonsattel J.-P.G., Yamamoto A., Sulzer D., Faust P.L. Lingo-1 expression is increased in essential tremor cerebellum and is present in the basket cell pinceau. Acta Neuropathol. (Berl.) 2013, 125:879-889. DOI 10.1007/s00401-013-1108-7.
128. Kwon H.S., Nakaya N., Abu-Asab M., Kim H.S., Tomarev S.I. Myocilin is involved in NgR1/Lingo-1-mediated oligodendrocyte differentiation and myelination of the optic nerve. J. Neurosci. 2014, 34:5539-5551. DOI 10.1523/JNEUROSCI.4731-13.2014.
129. Lange N., Dubray M.B., Lee J.E., Froimowitz M.P., Froehlich A., Adluru N., Wright B., Ravichandran C., Fletcher P.T., Bigler E.D., Alexander A.L., Lainhart J.E. Atypical diffusion tensor hemispheric asymmetry in autism. Autism Res. 2010, 3:350-358. DOI 10.1002/aur.162. (Off. J. Int. Soc. Autism Res.).
130. Lassmann H. Axonal injury in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2003, 74:695-697.
131. Lavebratt C., Trifunovski A., Persson A.-S., Wang F.-H., Klason T., Öhman I., Josephsson A., Olson L., Spenger C., Schalling M. Carbamazepine protects against megencephaly and abnormal expression of BDNF and Nogo signaling components in the mceph/mceph mouse. Neurobiol. Dis. 2006, 24:374-383. DOI 10.1016/j.nbd.2006.07.018.
132. Law A.J., Lipska B.K., Weickert C.S., Hyde T.M., Straub R.E., Hashimoto R., Harrison P.J., Kleinman J.E., Weinberger D.R. Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5' SNPs associated with the disease. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:6747-6752. DOI 0602002103 10.1073/pnas.0602002103.
133. Lee H., Raiker S.J., Venkatesh K., Geary R., Robak L.A., Zhang Y., Yeh H.H., Shrager P., Giger R.J. Synaptic function for the Nogo-66 receptor NgR1: regulation of dendritic spine morphology and activity-dependent synaptic strength. J. Neurosci. 2008, 28:2753-2765. DOI 10.1523/JNEUROSCI.5586-07.2008. (Off. J. Soc. Neurosci.).
134. Lee J.E., Bigler E.D., Alexander A.L., Lazar M., DuBray M.B., Chung M.K., Johnson M., Morgan J., Miller J.N., McMahon W.M., Lu J., Jeong E.-K., Lainhart J.E. Diffusion tensor imaging of white matter in the superior temporal gyrus and temporal stem in autism. Neurosci. Lett. 2007, 424:127-132. DOI 10.1016/j.neulet.2007.07.042.
135. Lee X., Yang Z., Shao Z., Rosenberg S.S., Levesque M., Pepinsky R.B., Qiu M., Miller R.H., Chan J.R., Mi S. NGF regulates the expression of axonal LINGO-1 to inhibit oligodendrocyte differentiation and myelination. J. Neurosci. 2007, 27:220-225. DOI 27/1/220 10.1523/JNEUROSCI.4175-06.2007.
136. Lee Y.H., Song G.G. Genome-wide pathway analysis in attention-deficit/hyperactivity disorder. Neurol. Sci. 2014, 35:1189-1196. DOI 10.1007/s10072-014-1671-2. (Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol.).
137. Lee Y., Mattai A., Long R., Rapoport J.L., Gogtay N., Addington A.M. Microduplications disrupting the MYT1L gene (2p25.3) are associated with schizophrenia. Psychiatr. Genet. 2012, 22:206-209. DOI 10.1097/YPG.0b013e328353ae3d.
138. Li H.S., Chen J.H., Wu W., Fagaly T., Zhou L., Yuan W., Dupuis S., Jiang Z.H., Nash W., Gick C., Ornitz D.M., Wu J.Y., Rao Y. Vertebrate slit, a secreted ligand for the transmembrane protein roundabout, is a repellent for olfactory bulb axons. Cell 1999, 96:807-818.
139. Lim K.O., Hedehus M., Moseley M., de Crespigny A., Sullivan E.V., Pfefferbaum A. Compromised white matter tract integrity in schizophrenia inferred from diffusion tensor imaging. Arch. Gen. Psychiatry 1999, 56:367-374.
140. Liu B.P., Fournier A., GrandPré T., Strittmatter S.M. Myelin-associated glycoprotein as a functional ligand for the Nogo-66 receptor. Science 2002, 297:1190-1193. DOI 10.1126/science.1073031.
141. Li W., Wang X., Zhao J., Lin J., Song X.Q., Yang Y., Jiang C., Xiao B., Yang G., Zhang H.X., Lv L.X. Association study of myelin transcription factor 1-like polymorphisms with schizophrenia in Han Chinese population. Genes Brain Behav. 2012, 11:87-93. DOI 10.1111/j.1601-183X.2011.00734.x.
142. Llorens F., Gil V., Iraola S., Carim-Todd L., Marti E., Estivill X., Soriano E., del Rio J.A., Sumoy L. Developmental analysis of Lingo-1/Lern1 protein expression in the mouse brain: interaction of its intracellular domain with Myt1l. Dev. Neurobiol. 2008, 68:521-541. DOI 10.1002/dneu.20607.
143. Lotta L.T., Conrad K., Cory-Slechta D., Schor N.F. Cerebellar Purkinje cell p75 neurotrophin receptor and autistic behavior. Transl. Psychiatry 2014, 4:e416. DOI 10.1038/tp.2014.55.
144. Louis E.D., Thawani S.P., Andrews H.F. Prevalence of essential tremor in a multiethnic, community-based study in northern Manhattan, New York, N.Y. Neuroepidemiology 2009, 32:208-214. DOI 10.1159/000195691.
145. Luo L. Actin cytoskeleton regulation in neuronal morphogenesis and structural plasticity. Annu. Rev. Cell Dev. Biol. 2002, 18:601-635. DOI 10.1146/annurev.cellbio.18.031802.150501.
146. Madrigal I., Martinez M., Rodriguez-Revenga L., Carrió A., Milà M. 12p13 rearrangements: 6Mb deletion responsible for ID/MCA and reciprocal duplication without clinical responsibility. Am. J. Med. Genet. A 2012, 158A:1071-1076. DOI 10.1002/ajmg.a.35287.
147. Marshall C.R., Noor A., Vincent J.B., Lionel A.C., Feuk L., Skaug J., Shago M., Moessner R., Pinto D., Ren Y., Thiruvahindrapduram B., Fiebig A., Schreiber S., Friedman J., Ketelaars C.E.J., Vos Y.J., Ficicioglu C., Kirkpatrick S., Nicolson R., Sloman L., Summers A., Gibbons C.A., Teebi A., Chitayat D., Weksberg R., Thompson A., Vardy C., Crosbie V., Luscombe S., Baatjes R., Zwaigenbaum L., Roberts W., Fernandez B., Szatmari P., Scherer S.W. Structural variation of chromosomes in autism spectrum disorder. Am. J. Hum. Genet. 2008, 82:477-488. DOI 10.1016/j.ajhg.2007.12.009.
148. Martinowich K., Schloesser R.J., Lu Y., Jimenez D.V., Paredes D., Greene J.S., Greig N.H., Manji H.K., Lu B. Roles of p75NTR, long-term depression, and cholinergic transmission in anxiety and acute stress coping. Biol. Psychiatry 2012, 71:75-83. DOI 10.1016/j.biopsych.2011.08.014. (Molecular Substrates of Neuroplasticity in Depression).
149. Maycox P.R., Kelly F., Taylor A., Bates S., Reid J., Logendra R., Barnes M.R., Larminie C., Jones N., Lennon M., Davies C., Hagan J.J., Scorer C.A., Angelinetta C., Akbar M.T., Akbar T., Hirsch S., Mortimer A.M., Barnes T.R.E., de Belleroche J. Analysis of gene expression in two large schizophrenia cohorts identifies multiple changes associated with nerve terminal function. Mol. Psychiatry 2009, 14:1083-1094. DOI 10.1038/mp.2009.18.
150. McGee A.W., Strittmatter S.M. The Nogo-66 receptor: focusing myelin inhibition of axon regeneration. Trends Neurosci. 2003, 26:193-198. DOI 10.1016/S0166-2236(03)00062-6.
151. McGee A.W., Yang Y., Fischer Q.S., Daw N.W., Strittmatter S.M. Experience-driven plasticity of visual cortex limited by myelin and Nogo receptor. Science 2005, 309:2222-2226. DOI 10.1126/science.1114362.
152. McInnes L.A., Nakamine A., Pilorge M., Brandt T., González P.J., Fallas M., Manghi E.R., Edelmann L., Glessner J., Hakonarson H., Betancur C., Buxbaum J.D. A large-scale survey of the novel 15q24 microdeletion syndrome in autism spectrum disorders identifies an atypical deletion that narrows the critical region. Mol. Autism 2010, 1:5. DOI 10.1186/2040-2392-1-5.
153. Meyer K.J., Axelsen M.S., Sheffield V.C., Patil S.R., Wassink T.H. Germline mosaic transmission of a novel duplication of PXDN and MYT1L to two male half-siblings with autism. Psychiatr. Genet. 2012, 22:137-140. DOI 10.1097/YPG.0b013e32834dc3f5.
154. Mi S., Blake Pepinsky R., Cadavid D. Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic. CNS Drugs 2013, DOI 10.1007/s40263-013-0068-8.
155. Mi S., Hu B., Hahm K., Luo Y., Kam Hui E.S., Yuan Q., Wong W.M., Wang L., Su H., Chu T.H., Guo J., Zhang W., So K.F., Pepinsky B., Shao Z., Graff C., Garber E., Jung V., Wu E.X., Wu W. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat. Med. 2007, 13:1228-1233. DOI nm1664 10.1038/nm1664.
156. Mi S., Lee X., Shao Z., Thill G., Ji B., Relton J., Levesque M., Allaire N., Perrin S., Sands B., Crowell T., Cate R.L., McCoy J.M., Pepinsky R.B. LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex. Nat. Neurosci. 2004, 7:221-228. DOI 10.1038/nn1188 nn1188 .
157. Mi S., Miller R.H., Lee X., Scott M.L., Shulag-Morskaya S., Shao Z., Chang J., Thill G., Levesque M., Zhang M., Hession C., Sah D., Trapp B., He Z., Jung V., McCoy J.M., Pepinsky R.B. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat. Neurosci. 2005, 8:745-751. DOI nn1460 10.1038/nn1460.
158. Mi S., Miller R.H., Tang W., Lee X., Hu B., Wu W., Zhang Y., Shields C.B., Zhang Y., Miklasz S., Shea D., Mason J., Franklin R.J.M., Ji B., Shao Z., Chédotal A., Bernard F., Roulois A., Xu J., Jung V., Pepinsky B. Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann. Neurol. 2009, 65:304-315. DOI 10.1002/ana.21581.
159. Mistry M., Gillis J., Pavlidis P. Genome-wide expression profiling of schizophrenia using a large combined cohort. Mol. Psychiatry 2012, DOI 10.1038/mp.2011.172 mp2011172 .
160. Moessner R., Marshall C.R., Sutcliffe J.S., Skaug J., Pinto D., Vincent J., Zwaigenbaum L., Fernandez B., Roberts W., Szatmari P., Scherer S.W. Contribution of SHANK3 mutations to autism spectrum disorder. Am. J. Hum. Genet. 2007, 81:1289-1297. DOI 10.1086/522590.
161. Morante-Redolat J.M., Gorostidi-Pagola A., Piquer-Sirerol S., Sáenz A., Poza J.J., Galán J., Gesk S., Sarafidou T., Mautner V.-F., Binelli S., Staub E., Hinzmann B., French L., Prud'homme J.-F., Passarelli D., Scannapieco P., Tassinari C.A., Avanzini G., Martí-Massó J.F., Kluwe L., Deloukas P., Moschonas N.K., Michelucci R., Siebert R., Nobile C., Pérez-Tur J., López de Munain A. Mutations in the LGI1/Epitempin gene on 10q24 cause autosomal dominant lateral temporal epilepsy. Hum. Mol. Genet. 2002, 11:1119-1128.
162. Mosyak L., Wood A., Dwyer B., Buddha M., Johnson M., Aulabaugh A., Zhong X., Presman E., Benard S., Kelleher K., Wilhelm J., Stahl M.L., Kriz R., Gao Y., Cao Z., Ling H.-P., Pangalos M.N., Walsh F.S., Somers W.S. The structure of the Lingo-1 ectodomain, a module implicated in central nervous system repair inhibition. J. Biol. Chem. 2006, 281:36378-36390. DOI 10.1074/jbc.M607314200.
163. Nguyen-Ba-Charvet K.T., Chédotal A. Role of Slit proteins in the vertebrate brain. J. Physiol. Paris 2002, 96:91-98.
164. Oda K., Matsuoka Y., Funahashi A., Kitano H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol. Syst. Biol. 2005, 1:2005.0010. DOI 10.1038/msb4100014.
165. O'Kane E.M., Stone T.W., Morris B.J. Increased long-term potentiation in the CA1 region of rat hippocampus via modulation of GTPase signalling or inhibition of Rho kinase. Neuropharmacology 2004, 46:879-887. DOI 10.1016/j.neuropharm.2003.11.020.
166. O'Kane E.M., Stone T.W., Morris B.J. Activation of Rho GTPases by synaptic transmission in the hippocampus. J. Neurochem. 2003, 87:1309-1312.
167. Okumura E., Fukuhara T., Yoshida H., Hanada Si S., Kozutsumi R., Mori M., Tachibana K., Kishimoto T. Akt inhibits Myt1 in the signalling pathway that leads to meiotic G2/M-phase transition. Nat. Cell Biol. 2002, 4:111-116. DOI 10.1038/ncb741.
168. Olsen D., Kaas M., Schwartz O., Nykjaer A., Glerup S. Loss of BDNF or its receptors in three mouse models has unpredictable consequences for anxiety and fear acquisition. Learn. Mem. 2013, 20:499-504. DOI 10.1101/lm.032045.113.
169. Onyango I.G., Tuttle J.B., Bennett J.P. Brain-derived growth factor and glial cell line-derived growth factor use distinct intracellular signaling pathways to protect PD cybrids from H2O2-induced neuronal death. Neurobiol. Dis. 2005, 20:141-154. DOI 10.1016/j.nbd.2005.02.009.
170. Papolos D.F., Faedda G.L., Veit S., Goldberg R., Morrow B., Kucherlapati R., Shprintzen R.J. Bipolar spectrum disorders in patients diagnosed with velo-cardio-facial syndrome: does a hemizygous deletion of chromosome 22q11 result in bipolar affective disorder?. Am. J. Psychiatry 1996, 153:1541-1547.
171. Park J.B., Yiu G., Kaneko S., Wang J., Chang J., He X.L., Garcia K.C., He Z. A TNF receptor family member, TROY, is a coreceptor with Nogo receptor in mediating the inhibitory activity of myelin inhibitors. Neuron 2005, 45:345-351. DOI S0896-6273(05)00012-7 10.1016/j.neuron.2004.12.040.
172. Park J.H., Gimbel D.A., GrandPre T., Lee J.-K., Kim J.-E., Li W., Lee D.H.S., Strittmatter S.M. Alzheimer precursor protein interaction with the Nogo-66 receptor reduces amyloid-beta plaque deposition. J. Neurosci. 2006, 26:1386-1395. DOI 10.1523/JNEUROSCI.3291-05.2006. (Off. J. Soc. Neurosci.).
173. Pepinsky R.B., Arndt J.W., Quan C., Gao Y., Quintero-Monzon O., Lee X., Mi S. Structure of the LINGO-1-anti-LINGO-1 Li81 antibody complex provides insights into the biology of LINGO-1 and the mechanism of action of the antibody therapy. J. Pharmacol. Exp. Ther. 2014, 350:110-123. DOI 10.1124/jpet.113.211771.
174. Pusch C.M., Zeitz C., Brandau O., Pesch K., Achatz H., Feil S., Scharfe C., Maurer J., Jacobi F.K., Pinckers A., Andreasson S., Hardcastle A., Wissinger B., Berger W., Meindl A. The complete form of X-linked congenital stationary night blindness is caused by mutations in a gene encoding a leucine-rich repeat protein. Nat. Genet. 2000, 26:324-327. DOI 10.1038/81627.
175. Rabizadeh S., Bredesen D.E. Ten years on: mediation of cell death by the common neurotrophin receptor p75(NTR). Cytokine Growth Factor Rev. 2003, 14:225-239.
176. Raghupathi R. Cell death mechanisms following traumatic brain injury. Brain Pathol. 2004, 14:215-222. (Zurich Switz.).
177. Raiker S.J., Lee H., Baldwin K.T., Duan Y., Shrager P., Giger R.J. Oligodendrocyte-myelin glycoprotein and Nogo negatively regulate activity-dependent synaptic plasticity. J. Neurosci. 2010, 30:12432-12445. DOI 10.1523/JNEUROSCI.0895-10.2010. (Off. J. Soc. Neurosci.).
178. Rajakumar N., Leung L.S., Ma J., Rajakumar B., Rushlow W. Altered neurotrophin receptor function in the developing prefrontal cortex leads to adult-onset dopaminergic hyperresponsivity and impaired prepulse inhibition of acoustic startle. Biol. Psychiatry 2004, 55:797-803. DOI 10.1016/j.biopsych.2003.12.015.
179. Royo N.C., Schouten J.W., Fulp C.T., Shimizu S., Marklund N., Graham D.I., McIntosh T.K. From cell death to neuronal regeneration: building a new brain after traumatic brain injury. J. Neuropathol. Exp. Neurol. 2003, 62:801-811.
180. Rüsch N., Weber M., Il'yasov K.A., Lieb K., Ebert D., Hennig J., van Elst L.T. Inferior frontal white matter microstructure and patterns of psychopathology in women with borderline personality disorder and comorbid attention-deficit hyperactivity disorder. NeuroImage 2007, 35:738-747. DOI 10.1016/j.neuroimage.2006.12.007.
181. Satoh J.-I., Onoue H., Arima K., Yamamura T. Nogo-A and nogo receptor expression in demyelinating lesions of multiple sclerosis. J. Neuropathol. Exp. Neurol. 2005, 64:129-138.
182. Satoh J., Tabunoki H., Yamamura T., Arima K., Konno H. TROY and LINGO-1 expression in astrocytes and macrophages/microglia in multiple sclerosis lesions. Neuropathol. Appl. Neurobiol. 2007, 33. DOI 10.1111/j.1365-2990.2006.00787.x.
183. Schmitt A., Wilczek K., Blennow K., Maras A., Jatzko A., Petroianu G., Braus D.F., Gattaz W.F. Altered thalamic membrane phospholipids in schizophrenia: a postmortem study. Biol. Psychiatry 2004, 56:41-45. DOI 10.1016/j.biopsych.2004.03.019.
184. Schwab J.M., Tuli S.K., Failli V. The Nogo receptor complex: confining molecules to molecular mechanisms. Trends Mol. Med. 2006, 12:293-297. DOI S1471-4914(06)00093-1 10.1016/j.molmed.2006.05.001.
185. Segal R.A. Selectivity in neurotrophin signaling: theme and variations. Annu. Rev. Neurosci. 2003, 26:299-330. DOI 10.1146/annurev.neuro.26.041002.131421 041002.131421 .
186. Semrud-Clikeman M., Steingard R.J., Filipek P., Biederman J., Bekken K., Renshaw P.F. Using MRI to examine brain-behavior relationships in males with attention deficit disorder with hyperactivity. J. Am. Acad. Child Adolesc. Psychiatry 2000, 39:477-484. DOI 10.1097/00004583-200004000-00017.
187. Shahed J., Jankovic J. Exploring the relationship between essential tremor and Parkinson's disease. Parkinsonism Relat. Disord. 2007, 13:67-76. DOI 10.1016/j.parkreldis.2006.05.033.
188. Shao Z., Browning J.L., Lee X., Scott M.L., Shulga-Morskaya S., Allaire N., Thill G., Levesque M., Sah D., McCoy J.M., Murray B., Jung V., Pepinsky R.B., Mi S. TAJ/TROY, an orphan TNF receptor family member, binds Nogo-66 receptor 1 and regulates axonal regeneration. Neuron 2005, 45:353-359. DOI S0896-6273(05)00011-5 10.1016/j.neuron.2004.12.050.
189. Sharp A.J., Selzer R.R., Veltman J.A., Gimelli S., Gimelli G., Striano P., Coppola A., Regan R., Price S.M., Knoers N.V., Eis P.S., Brunner H.G., Hennekam R.C., Knight S.J.L., de Vries B.B.A., Zuffardi O., Eichler E.E. Characterization of a recurrent 15q24 microdeletion syndrome. Hum. Mol. Genet. 2007, 16:567-572. DOI 10.1093/hmg/ddm016.
190. Shatz C.J. MHC class I: an unexpected role in neuronal plasticity. Neuron 2009, 64:40-45. DOI 10.1016/j.neuron.2009.09.044.
191. Shenton M.E., Dickey C.C., Frumin M., McCarley R.W. A review of MRI findings in schizophrenia. Schizophr. Res. 2001, 49:1-52.
192. Silva I.M.W., Rosenfeld J., Antoniuk S.A., Raskin S., Sotomaior V.S. A 1.5Mb terminal deletion of 12p associated with autism spectrum disorder. Gene 2014, 542:83-86. DOI 10.1016/j.gene.2014.02.058.
193. Sinibaldi L., De Luca A., Bellacchio E., Conti E., Pasini A., Paloscia C., Spalletta G., Caltagirone C., Pizzuti A., Dallapiccola B. Mutations of the Nogo-66 receptor (RTN4R) gene in schizophrenia. Hum. Mutat. 2004, 24:534-535. DOI 10.1002/humu.9292.
194. Spanaki C., Plaitakis A. Essential tremor in Parkinson's disease kindreds from a population of similar genetic background. Mov. Disord. 2009, 24:1662-1668. DOI 10.1002/mds.22655. (Off. J. Mov. Disord. Soc.).
195. Sporn A., Addington A., Reiss A.L., Dean M., Gogtay N., Potocnik U., Greenstein D., Hallmayer J., Gochman P., Lenane M., Baker N., Tossell J., Rapoport J.L. 22q11 deletion syndrome in childhood onset schizophrenia: an update. Mol. Psychiatry 2004, 9:225-226. DOI 10.1038/sj.mp.4001477.
196. Stefansson H., Steinberg S., Petursson H., Gustafsson O., Gudjonsdottir I.H., Jonsdottir G.A., Palsson S.T., Jonsson T., Saemundsdottir J., Bjornsdottir G., Böttcher Y., Thorlacius T., Haubenberger D., Zimprich A., Auff E., Hotzy C., Testa C.M., Miyatake L.A., Rosen A.R., Kristleifsson K., Rye D., Asmus F., Schöls L., Dichgans M., Jakobsson F., Benedikz J., Thorsteinsdottir U., Gulcher J., Kong A., Stefansson K. Variant in the sequence of the LINGO1 gene confers risk of essential tremor. Nat. Genet. 2009, 41:277-279. DOI 10.1038/ng.299.
197. Stein T., Walmsley A.R. The leucine-rich repeats of LINGO-1 are not required for self-interaction or interaction with the amyloid precursor protein. Neurosci. Lett. 2012, 509:9-12. DOI 10.1016/j.neulet.2011.11.029.
198. Stephan K.E., Baldeweg T., Friston K.J. Synaptic plasticity and dysconnection in schizophrenia. Biol. Psychiatry 2006, 59:929-939. DOI 10.1016/j.biopsych.2005.10.005.
199. Stone E.M., Fingert J.H., Alward W.L., Nguyen T.D., Polansky J.R., Sunden S.L., Nishimura D., Clark A.F., Nystuen A., Nichols B.E., Mackey D.A., Ritch R., Kalenak J.W., Craven E.R., Sheffield V.C. Identification of a gene that causes primary open angle glaucoma. Science 1997, 275:668-670.
200. Stork O., Pape H.-C. Fear memory and the amygdala: insights from a molecular perspective. Cell Tissue Res. 2002, 310:271-277. DOI 10.1007/s00441-002-0656-2.
201. Suzuki K., Hashimoto K., Iwata Y., Nakamura K., Tsujii M., Tsuchiya K.J., Sekine Y., Suda S., Sugihara G., Matsuzaki H., Sugiyama T., Kawai M., Minabe Y., Takei N., Mori N. Decreased serum levels of epidermal growth factor in adult subjects with high-functioning autism. Biol. Psychiatry 2007, 62:267-269. DOI 10.1016/j.biopsych.2006.08.001. (Mechanisms of Circuit Dysfunction in Neurodevelopmental Disorders).
202. Swaminathan V., Pereira A.M., Tsai-Chin, Weickert C.S., Sundram S. Altered epidermal growth factor receptor expression in dorsolateral prefrontal cortex may be implicated in sucidality in schizophrenia. Biomarkers and Imaging in Schizophrenia Theme C: Disorders of the Nervous System. Presented at the Neuroscience 2013, Neuroscience 2013 2013.
203. Szeszko P.R., Ardekani B.A., Ashtari M., Malhotra A.K., Robinson D.G., Bilder R.M., Lim K.O. White matter abnormalities in obsessive-compulsive disorder: a diffusion tensor imaging study. Arch. Gen. Psychiatry 2005, 62:782-790. DOI 10.1001/archpsyc.62.7.782.
204. Tabiner M., Youings S., Dennis N., Baldwin D., Buis C., Mayers A., Jacobs P.A., Crolla J.A. Failure to find DUP25 in patients with anxiety disorders, in control individuals, or in previously reported positive control cell lines. Am. J. Hum. Genet. 2003, 72:535-538. DOI 10.1086/367777.
205. Tang C.Y., Friedman J., Shungu D., Chang L., Ernst T., Stewart D., Hajianpour A., Carpenter D., Ng J., Mao X., Hof P.R., Buchsbaum M.S., Davis K., Gorman J.M. Correlations between diffusion tensor imaging (DTI) and magnetic resonance spectroscopy (1H MRS) in schizophrenic patients and normal controls. BMC Psychiatry 2007, 7:25. DOI 1471-244X-7-25 10.1186/1471-244X-7-25.
206. Thevenon J., Callier P., Andrieux J., Delobel B., David A., Sukno S., Minot D., Mosca Anne L., Marle N., Sanlaville D., Bonnet M., Masurel-Paulet A., Levy F., Gaunt L., Farrell S., Le Caignec C., Toutain A., Carmignac V., Mugneret F., Clayton-Smith J., Thauvin-Robinet C., Faivre L. 12p13.33 microdeletion including ELKS/ERC1, a new locus associated with childhood apraxia of speech. Eur. J. Hum. Genet. 2013, 21:82-88. DOI 10.1038/ejhg.2012.116.
207. Thiebaut de Schotten M., Bakardjian H., Lista S., Teipel S., Dyrba M., Filippi M., Frisoni G.B., Fellgiebel A., Bokde A., Klöppel S., Froelich L., Barkhof F., Dubois B., Hampel H. Advanced diffusion weighting imaging (DWI) tractography of the limbic system: novel biomarkers of neurodegenerative changes during progression/conversion from cognitive normality to AD dementia. Alzheimers Dement. J. Alzheimers Assoc. 2014, 10:P541-P542. DOI 10.1016/j.jalz.2014.05.868.
208. Thompson H.J., Marklund N., LeBold D.G., Morales D.M., Keck C.A., Vinson M., Royo N.C., Grundy R., McIntosh T.K. Tissue sparing and functional recovery following experimental traumatic brain injury is provided by treatment with an anti-myelin-associated glycoprotein antibody. Eur. J. Neurosci. 2006, 24:3063-3072. DOI 10.1111/j.1460-9568.2006.05197.x.
209. Thompson Ray M., Weickert C.S., Wyatt E., Webster M.J. Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. J. Psychiatry Neurosci. 2011, 36:195-203. DOI 10.1503/jpn.100048.
210. Timmons S., Coakley M.F., Moloney A.M., O' Neill C. Akt signal transduction dysfunction in Parkinson's disease. Neurosci. Lett. 2009, 467:30-35. DOI 10.1016/j.neulet.2009.09.055.
211. Tiwari A.K., Deshpande S.N., Rao A.R., Bhatia T., Mukit S.R., Shriharsh V., Lerer B., Nimagaonkar V.L., Thelma B.K. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism. Pharmacogenomics J. 2005, 5:60-69. DOI 10.1038/sj.tpj.6500282.
212. Tkachev D., Mimmack M.L., Ryan M.M., Wayland M., Freeman T., Jones P.B., Starkey M., Webster M.J., Yolken R.H., Bahn S. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003, 362:798-805. DOI S0140-6736(03)14289-4 10.1016/S0140-6736(03)14289-4.
213. Toyoda T., Nakamura K., Yamada K., Thanseem I., Anitha A., Suda S., Tsujii M., Iwayama Y., Hattori E., Toyota T., Miyachi T., Iwata Y., Suzuki K., Matsuzaki H., Kawai M., Sekine Y., Tsuchiya K., Sugihara G., Ouchi Y., Sugiyama T., Takei N., Yoshikawa T., Mori N. SNP analyses of growth factor genes EGF, TGFβ-1, and HGF reveal haplotypic association of EGF with autism. Biochem. Biophys. Res. Commun. 2007, 360:715-720. DOI 10.1016/j.bbrc.2007.06.051.
214. Tran J., Palaparthy R., Zhao J., Brosofsky K., Ray S., Rana J., Cadavid D. Safety, tolerability and pharmacokinetics of the anti-LINGO-1 monoclonal antibody BIIB033 in healthy volunteers and subjects with multiple sclerosis (P02.021). Neurology 2012, 78:P02.021. (Meeting Abstracts 1), http://www.neurology.org/cgi/content/meeting_abstract/78/1_MeetingAbstracts/P02.021. 10.1212/WNL.78.1_MeetingAbstracts.P02.021.
215. Tran J.Q., Rana J., Barkhof F., Melamed I., Gevorkyan H., Wattjes M.P., Jong R., de Brosofsky K., Ray S., Xu L., Zhao J., Parr E., Cadavid D. Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurol. Neuroimmunol. Neuroinflamm. 2014, 1:e18. DOI 10.1212/NXI.0000000000000018.
216. Trifunovski A., Josephson A., Bickford P.C., Olson L., Brené S. Selective decline of Nogo mRNA in the aging brain. NeuroReport 2006, 17:913-916. DOI 10.1097/01.wnr.0000221831.95598.a3.
217. Trifunovski A., Josephson A., Ringman A., Brene S., Spenger C., Olson L. Neuronal activity-induced regulation of Lingo-1. NeuroReport 2004, 15:2397-2400. DOI 00001756-200410250-00019 .
218. Uranova N., Orlovskaya D., Vikhreva O., Zimina I., Kolomeets N., Vostrikov V., Rachmanova V. Electron microscopy of oligodendroglia in severe mental illness. Brain Res. Bull. 2001, 55:597-610.
219. Vana A.C., Lucchinetti C.F., Le T.Q., Armstrong R.C. Myelin transcription factor 1 (Myt1) expression in demyelinated lesions of rodent and human CNS. Glia 2007, 55:687-697. DOI 10.1002/glia.20492.
220. Vilariño-Güell C., Ross O.A., Wider C., Jasinska-Myga B., Cobb S.A., Soto-Ortolaza A.I., Kachergus J.M., Keeling B.H., Dachsel J.C., Melrose H.L., Behrouz B., Wszolek Z.K., Uitti R.J., Aasly J.O., Rajput A., Farrer M.J. LINGO1 rs9652490 is associated with essential tremor and Parkinson disease. Parkinsonism Relat. Disord. 2010, 16:109-111. DOI 10.1016/j.parkreldis.2009.08.006.
221. Vilariño-Güell C., Wider C., Ross O.A., Jasinska-Myga B., Kachergus J., Cobb S.A., Soto-Ortolaza A.I., Behrouz B., Heckman M.G., Diehl N.N., Testa C.M., Wszolek Z.K., Uitti R.J., Jankovic J., Louis E.D., Clark L.N., Rajput A., Farrer M.J. LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease. Neurogenetics 2010, 11:401-408. DOI 10.1007/s10048-010-0241-x.
222. Von Schack D., Casademunt E., Schweigreiter R., Meyer M., Bibel M., Dechant G. Complete ablation of the neurotrophin receptor p75NTR causes defects both in the nervous and the vascular system. Nat. Neurosci. 2001, 4:977-978. DOI 10.1038/nn730.
223. Vourc'h P., Moreau T., Arbion F., Marouillat-Védrine S., Müh J.-P., Andres C. Oligodendrocyte myelin glycoprotein growth inhibition function requires its conserved leucine-rich repeat domain, not its glycosylphosphatidyl-inositol anchor. J. Neurochem. 2003, 85:889-897.
224. Vrijenhoek T., Buizer-Voskamp J.E., van der Stelt I., Strengman E., Sabatti C., Geurts van Kessel A., Brunner H.G., Ophoff R.A., Veltman J.A. Recurrent CNVs disrupt three candidate genes in schizophrenia patients. Am. J. Hum. Genet. 2008, 83:504-510. DOI S0002-9297(08)00501-6 10.1016/j.ajhg.2008.09.011.
225. Walterfang M., Velakoulis D., Whitford T.J., Pantelis C. Understanding aberrant white matter development in schizophrenia: an avenue for therapy?. Expert Rev. Neurother. 2011, 11:971-987. DOI 10.1586/ern.11.76.
226. Walterfang M., Wood S.J., Velakoulis D., Pantelis C. Neuropathological, neurogenetic and neuroimaging evidence for white matter pathology in schizophrenia. Neurosci. Biobehav. Rev. 2006, 30:918-948. DOI 10.1016/j.neubiorev.2006.02.001.
227. Wang C.-J., Qu C.-Q., Zhang J., Fu P.-C., Guo S.-G., Tang R.-H. Lingo-1 inhibited by RNA interference promotes functional recovery of experimental autoimmune encephalomyelitis. Anat. Rec. 2014, 297:2356-2363. DOI 10.1002/ar.22988.
228. Wang K.C., Kim J.A., Sivasankaran R., Segal R., He Z. P75 interacts with the Nogo receptor as a co-receptor for Nogo, MAG and OMgp. Nature 2002, 420:74-78. DOI 10.1038/nature01176.
229. Wang K.C., Kim J.A., Sivasankaran R., Segal R., He Z. P75 interacts with the Nogo receptor as a co-receptor for Nogo, MAG and OMgp. Nature 2002, 420:74-78. DOI 10.1038/nature01176.
230. Wang K.C., Koprivica V., Kim J.A., Sivasankaran R., Guo Y., Neve R.L., He Z. Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth. Nature 2002, 417:941-944. DOI 10.1038/nature00867.
231. Wang L., Chiang H.-C., Wu W., Liang B., Xie Z., Yao X., Ma W., Du S., Zhong Y. Epidermal growth factor receptor is a preferred target for treating Amyloid-β-induced memory loss. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:16743-16748. DOI 10.1073/pnas.1208011109.
232. Wang T., Zeng Z., Li T., Liu J., Li J., Li Y., Zhao Q., Wei Z., Wang Y., Li B., Feng G., He L., Shi Y. Common SNPs in myelin transcription factor 1-like (MYT1L): association with major depressive disorder in the Chinese Han population. PLoS ONE 2010, 5:e13662. DOI 10.1371/journal.pone.0013662.
233. Weidenhofer J., Bowden N.A., Scott R.J., Tooney P.A. Altered gene expression in the amygdala in schizophrenia: up-regulation of genes located in the cytomatrix active zone. Mol. Cell. Neurosci. 2006, 31:243-250. DOI 10.1016/j.mcn.2005.09.013.
234. Weiland Y., Kraus J., Speicher M.R. A multicolor FISH assay does not detect DUP25 in control individuals or in reported positive control cells. Am. J. Hum. Genet. 2003, 72:1349-1352. DOI 10.1086/375168.
235. Weinberger D.R., Berman K.F., Zec R.F. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia, I. Regional cerebral blood flow evidence. Arch. Gen. Psychiatry 1986, 43:114-124.
236. Wilson F.H., Kahle K.T., Sabath E., Lalioti M.D., Rapson A.K., Hoover R.S., Hebert S.C., Gamba G., Lifton R.P. Molecular pathogenesis of inherited hypertension with hyperkalemia: the Na-Cl cotransporter is inhibited by wild-type but not mutant WNK4. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:680-684. DOI 10.1073/pnas.242735399.
237. Woodin M., Wang P.P., Aleman D., McDonald-McGinn D., Zackai E., Moss E. Neuropsychological profile of children and adolescents with the 22q11.2 microdeletion. Genet. Med. 2001, 3:34-39. DOI 10.1097/00125817-200101000-00008.
238. Wu Y.-R., Tan E.-K., Chen C.-M., Kumar P.M., Lee-Chen G.-J., Chen S.-T. Genetic analysis of "leucine-rich repeat (LRR) and immunoglobulin (Ig) domain-containing, Nogo receptor-interacting protein-1 (LINGO1)" in two independent Chinese parkinson's disease populations. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2011, 156B:99-103. DOI 10.1002/ajmg.b.31124. (Off. Publ. Int. Soc. Psychiatr. Genet.).
239. Wu Y., Wang X., Xu W., Liu W., Fang F., Ding J., Song Y., Chen S. Genetic variation in LINGO-1 (rs9652490) and risk of Parkinson's disease: twelve studies and a meta-analysis. Neurosci. Lett. 2012, 522:67-72. DOI 10.1016/j.neulet.2012.06.018.
240. Xu B., English J.M., Wilsbacher J.L., Stippec S., Goldsmith E.J., Cobb M.H. WNK1, a novel mammalian serine/threonine protein kinase lacking the catalytic lysine in subdomain II. J. Biol. Chem. 2000, 275:16795-16801.
241. Xu K., Anderson T.R., Neyer K.M., Lamparella N., Jenkins G., Zhou Z., Yuan Q., Virkkunen M., Lipsky R.H. Nucleotide sequence variation within the human tyrosine kinase B neurotrophin receptor gene: association with antisocial alcohol dependence. Pharmacogenomics J. 2007, 7:368-379. DOI 10.1038/sj.tpj.6500430.
242. Yu S.-X., Li S., Shu H.-F., Zhang C.-Q., Liu S.-Y., Yang H. Expression of the Nogo-A system in cortical lesions of pediatric patients with tuberous sclerosis complex and focal cortical dysplasia type IIb. J. Neuropathol. Exp. Neurol. 2012, 71:665-677. DOI 10.1097/NEN.0b013e31825d6585.
243. Zambrowicz B.P., Abuin A., Ramirez-Solis R., Richter L.J., Piggott J., BeltrandelRio H., Buxton E.C., Edwards J., Finch R.A., Friddle C.J., Gupta A., Hansen G., Hu Y., Huang W., Jaing C., Key B.W., Kipp P., Kohlhauff B., Ma Z.-Q., Markesich D., Payne R., Potter D.G., Qian N., Shaw J., Schrick J., Shi Z.-Z., Sparks M.J., Van Sligtenhorst I., Vogel P., Walke W., Xu N., Zhu Q., Person C., Sands A.T. Wnk1 kinase deficiency lowers blood pressure in mice: a gene-trap screen to identify potential targets for therapeutic intervention. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:14109-14114. DOI 10.1073/pnas.2336103100.
244. Zhang Z., Xu X., Zhang Y., Zhou J., Yu Z., He C. LINGO-1 interacts with WNK1 to regulate nogo-induced inhibition of neurite extension. J. Biol. Chem. 2009, 284:15717-15728. DOI M808751200 10.1074/jbc.M808751200.
245. Zhou Q., Choi G., Anderson D.J. The bHLH transcription factor Olig2 promotes oligodendrocyte differentiation in collaboration with Nkx2.2. Neuron 2001, 31:791-807.
246. Zhu G., Bartsch O., Skrypnyk C., Rotondo A., Akhtar L.A., Harris C., Virkkunen M., Cassano G., Goldman D. Failure to detect DUP25 in lymphoblastoid cells derived from patients with panic disorder and control individuals representing European and American populations. Eur. J. Hum. Genet. 2004, 12:505-508. DOI 10.1038/sj.ejhg.5201181.
247. Zhu H.-Y., Guo H.-F., Hou H.-L., Liu Y.-J., Sheng S.-L., Zhou J.-N. Increased expression of the Nogo receptor in the hippocampus and its relation to the neuropathology in Alzheimer's disease. Hum. Pathol. 2007, 38:426-434. DOI 10.1016/j.humpath.2006.09.010.